Teamwork Financial Advisors LLC Sells 8,835 Shares of Amgen Inc. $AMGN

Key Points

• Teamwork Financial Advisors sharply reduced its Amgen stake, selling 8,835 shares, or 89.8% of its position, and retaining 1,000 shares valued at approximately $362,000.
• Amgen reported strong quarterly results, with earnings of $6.29 per share and revenue of $10.05 billion, beating analyst expectations. Management issued full-year 2026 earnings guidance of $22.30 to $23.50 per share.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 payout and a 2.5% yield, while analysts maintained a broadly mixed outlook with a consensus “Hold” rating.

Teamwork Financial Advisors LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 89.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,000 shares of the medical research company's stock after selling 8,835 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Amgen were worth $362,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. High Note Wealth LLC grew its holdings in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock valued at $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. lifted its holdings in Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock worth $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC lifted its holdings in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company's stock worth $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management boosted its position in Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company's stock worth $456,000 after purchasing an additional 29 shares during the last quarter. Finally, Breakwater Capital Group boosted its position in Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company's stock worth $717,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company's stock.

Amgen Price Performance

Amgen stock opened at $410.95 on Friday. Amgen Inc. has a one year low of $269.77 and a one year high of $418.40. The business has a fifty day moving average price of $362.77 and a 200-day moving average price of $356.24. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $221.79 billion, a P/E ratio of 25.54, a PEG ratio of 3.77 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company's revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.73 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Mizuho raised their target price on Amgen from $295.00 to $303.00 and gave the company a "neutral" rating in a research report on Tuesday, June 16th. Barclays boosted their price target on shares of Amgen from $350.00 to $360.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 29th. Sanford C. Bernstein raised their price objective on shares of Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a report on Thursday. Citigroup lifted their price objective on shares of Amgen from $345.00 to $405.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Truist Financial boosted their target price on shares of Amgen from $340.00 to $362.00 and gave the company a "hold" rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $370.07.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source